Thyroid cancer, nonmedullary, 2
MONDO:0008566Also known as: thyroid cancer, nonmedullary, 2, thyroid cancer, nonmedullary, 2, autosomal dominant, somatic mutation, thyroid cancer, nonmedullary, type 2, thyroid carcinoma, follicular, autosomal dominant, somatic mutation, thyroid carcinoma, follicular, somatic, FTC, NMTC2, thyroid cancer, follicular
2765 clinical trials for this condition and its sub-types, 4 tagged with Thyroid cancer, nonmedullary, 2 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New combo therapy shows promise for Radioiodine-Resistant thyroid cancer
Disease control OngoingThis phase 2 trial tests a combination of the immunotherapy drug PDR001 with either trametinib or dabrafenib in 19 patients with thyroid cancer that no longer responds to radioiodine treatment. The goal is to see if the combination can shrink tumors. The study is active but no lo…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for Hard-to-Treat thyroid cancer: drug slows tumor growth in Late-Stage trial
Disease control OngoingThis study tests whether the drug cabozantinib can slow tumor growth in people with advanced thyroid cancer that no longer responds to standard treatments like radioiodine or other targeted therapies. About 187 participants will receive either cabozantinib or a placebo pill. The …
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC